Pipeline
The Science
About us
Investors
News

Hit enter to search or ESC to close

Dr David Stamler’s Biotech Showcase Presentation

January 7, 2019 Kerry Rowe

Prana Biotechnology BSC Presntation 20180107 FINAL

Post navigation

Prana Presents at Biotech Showcase

Prana receives Orphan Designation for PBT434 for treatment of MSA

Related Posts

Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program

October 19, 2021November 9, 2021

Prana to Present at Cowen & Company Health Care Conference on March 4th in Boston, MA

July 17, 2013

European Commission Approves PBT2 Orphan Designation for Huntington’s Disease

June 1, 2015

Recent Posts

WEBCAST LINK: H.C. Wainwright BIOCONNECT Virtual Conference
Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson’s and Alzheimer’s
Alterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial
Alterity Therapeutics to Participate in Two Upcoming Investor Conferences

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065